本文關(guān)鍵詞：低劑量阿立哌唑?qū)Ψ脢W氮平的精神分裂癥患者代謝及生活質(zhì)量的影響　出處：《中國新藥與臨床雜志》2015年12期 　論文類型：期刊論文

  更多相關(guān)文章： 精神分裂癥 奧氮平 阿立哌唑 代謝綜合征 生活質(zhì)量

【摘要】：目的評估低劑量阿立哌唑合并奧氮平治療精神分裂癥對患者安全性、代謝和生活質(zhì)量的影響。方法篩選符合入組條件的服用固定劑量奧氮平10~20 mg·d~(-1)的患者120例,隨機(jī)分為阿立哌唑組[阿立哌唑10 mg·d~(-1)+奧氮平(15.12±1.95)mg·d~(-1)]和對照組[奧氮平(14.95±2.08)mg·d~(-1)]各60例,進(jìn)行為期12周的非盲、平行對照研究。阿立哌唑10 mg頓服,奧氮平維持入組時劑量直至整個研究結(jié)束。分別于基線和4、8、12周末進(jìn)行生命體征測量、體重變化和體重指數(shù)(BMI)測量和計算;在基線和12周末進(jìn)行陽性與陰性癥狀量表(PANSS)、臨床總體印象量表-疾病嚴(yán)重程度(CGI-S)評估和精神分裂癥患者生活質(zhì)量量表(SQLS)評估,同時進(jìn)行血糖、血脂、血壓等代謝和生物學(xué)安全性指標(biāo)檢測和不良事件觀察。結(jié)果阿立哌唑組體重和BMI各時點(diǎn)與基線比較顯著下降(P0.05),其代謝指標(biāo)在治療過程中無顯著變化(P0.05),空腹血糖、三酰甘油、總膽固醇與對照組比較有顯著差異(P0.05)。治療12周末,兩組PANSS總分和CGI-S分治療前后組內(nèi)比較均有顯著差異(P0.05),且兩組間無顯著差異(P0.05);阿立哌唑組SQLS的3個分量表分與基線比較均無顯著差異(P0.05),而對照組的心理社會分量表分高于基線(P0.05),兩組間比較有顯著差異(P=0.017)。兩組藥物不良事件均為輕或中度,多數(shù)能耐受,發(fā)生率相當(dāng)(P0.05)。結(jié)論使用奧氮平的穩(wěn)定期精神分裂癥患者,短期內(nèi)合用低劑量阿立哌唑10 mg·d~(-1)治療,能明顯改善血糖、血脂等代謝參數(shù),且有明顯降低體重的趨勢,不良事件發(fā)生率較低,對精神分裂癥患者的生活質(zhì)量無明顯影響。
[Abstract]:Objective to evaluate the safety of low dose aripiprazole combined with olanzapine in the treatment of schizophrenia. Effects of metabolism and quality of life. Methods 120 patients who were treated with fixed dose of olanzapine 1020 mg 路dan-1) were randomly divided into two groups: aripiprazole group. [Aripiprazole 10 mg 路dan-1) olanzapine 15.12 鹵1.95 mg 路dan-1] and control group. [Sixty patients with olanzapine (14.95 鹵2.08mg 路dan-1) were given a 12-week, non-blind, parallel controlled study. Aripiprazole was given orally for 10 mg. The dose of olanzapine was maintained until the end of the whole study. Vital signs, body mass change and body mass index (BMIs) were measured and calculated at baseline and at the end of 12 weeks. The positive and negative symptom scale (PANSS) was carried out at baseline and at the end of 12 weeks. General impression scale (GIM)-severity of disease (CGI-S) and schizophrenia quality of life (QOL) were evaluated, and blood glucose and blood lipid were also evaluated. Results the body weight and BMI of aripiprazole group decreased significantly compared with baseline (P0.05). There was no significant change in the metabolic parameters during the treatment. Fasting blood glucose, triglyceride, total cholesterol were significantly different from those in the control group (P 0.05). After 12 weeks of treatment, there were significant differences between the two groups. The total score of PANSS and the score of CGI-S in the two groups were significantly different before and after treatment (P 0.05), and there was no significant difference between the two groups (P 0.05). There was no significant difference between the three subscales of SQLS and baseline in aripiprazole group (P 0.05), but the scores of psychosocial subscale in control group were higher than those in baseline group (P 0.05). There was significant difference between the two groups. The adverse events of the two groups were mild or moderate, and most of them could be tolerated. Conclusion the treatment of olanzapine combined with low dose of aripiprazole 10 mg 路dl can significantly improve blood glucose in patients with stable schizophrenia. The metabolic parameters such as blood lipids had a tendency to lower body weight and the incidence of adverse events was lower. There was no significant effect on the quality of life of schizophrenic patients.
【作者單位】： 新鄉(xiāng)醫(yī)學(xué)院第二附屬醫(yī)院精神七科;
【基金】：國家自然科學(xué)基金(81371472) 河南省科技廳2012年科技發(fā)展計劃(124200510019)
【分類號】：R749.3
【正文快照】： Effects of low-dose aripiprazole on metabolic profiles and quality of life ofschizophrenic patients with taking olanzapineZHAO Jing-yuan,LI Wen-qiang,GU Xiao-jing,AI Xiao-qing,HUA Ting-ting,L婬Lu-xian(The 7th Department of Psychiatry,the Second Affiliate，

本文編號：1405476